Advancing Treatment for Secondary Mitral Regurgitation: The Rise of Transcatheter Therapies
Secondary mitral regurgitation (SMR) is the most common valvular disease in the United States. It occurs when the mitral valve fails to close properly, not because of a primary defect in the valve itself, but due to changes in the heart’s structure, often associated with heart failure. While medical management remains the first line of defense, transcatheter interventions are transforming how clinicians treat patients who don’t respond to traditional therapies.
The shift toward minimally invasive procedures offers hope for patients who are too frail for open-heart surgery or those who continue to experience symptoms despite optimal medication. From edge-to-edge repair to full valve replacement, the landscape of SMR management is expanding rapidly.
The Foundation: Medical Therapy and Pre-Intervention Steps
Before considering an invasive procedure, guideline-directed medical therapy (GDMT) serves as the cornerstone of SMR treatment. However, the effectiveness of GDMT is often hindered by patient intolerance, compliance issues, or underutilization.
For qualifying patients, physicians prioritize two key interventions before moving to transcatheter options:
- Cardiac Resynchronization Therapy (CRT): Used to improve heart pumping efficiency.
- Coronary Revascularization: Addressing blocked arteries to improve overall cardiac function.
Transcatheter Edge-to-Edge Repair (TEER)
Transcatheter edge-to-edge repair (TEER), also known as M-TEER, is a minimally invasive procedure that uses a clip to join the mitral valve leaflets. This effectively reduces the amount of blood leaking backward into the left atrium.
TEER is now an established treatment for severe mitral regurgitation in patients with drug-refractory heart failure. According to ACC/AHA guidelines, TEER is a Class IIa recommendation for patients with severe, symptomatic SMR who meet the inclusion criteria of the COAPT trial. Research is ongoing to determine if this benefit extends to patients with mild to moderate SMR or those with severe left ventricle (LV) dysfunction.
In some specialized cases, TEER has shown efficacy for exercise-induced mitral regurgitation, even in patients who did not respond to cardiac resynchronization therapy (Cureus).
Transcatheter Mitral Valve Replacement (TMVR)
For patients who aren’t candidates for TEER, transcatheter mitral valve replacement (TMVR) is an emerging alternative. This involves inserting a new valve via a transseptal or transapical approach.
While early trials show promise, TMVR presents more challenges than other transcatheter procedures. It is more technically demanding to implant and requires patients to commit to long-term anticoagulation therapy to prevent clots (ACC).
Comparing Surgical and Transcatheter Approaches
Surgical options, such as surgical valve repair or replacement, are generally given a Class IIb recommendation when performed alone and a Class IIa recommendation when done during other cardiac surgeries. Some clinicians compare surgical repair using restrictive mitral annuloplasty (RMA) against TEER to determine the best long-term outcomes for SMR patients (PMC).
The Importance of the Multidisciplinary Heart Team
Because SMR is complex, the “best practice” for management is a multidisciplinary heart team approach. This team collaborates to assess the timing of treatment, optimize medical therapy, and choose the most appropriate intervention for each patient.
Precise diagnosis and procedural planning rely heavily on advanced imaging, including:
- Transesophageal echocardiography (TEE)
- Cardiac magnetic resonance (CMR)
- Cardiac computed tomography (CT)
- GDMT First: Medical therapy is the primary treatment, with CRT and revascularization considered before interventions.
- TEER Efficiency: TEER is a Class IIa recommendation for severe, symptomatic SMR patients meeting COAPT criteria.
- Replacement Challenges: TMVR is promising but more technically difficult and requires long-term anticoagulation.
- Team-Based Care: A multidisciplinary heart team using advanced imaging (TEE, CMR, CT) is essential for optimal patient outcomes.
Frequently Asked Questions
What is the difference between TEER and TMVR?
TEER uses a clip to repair the existing valve by joining the leaflets together. TMVR replaces the entire malfunctioning valve with a new prosthetic valve.
Who is a candidate for transcatheter repair?
Patients with severe, symptomatic secondary mitral regurgitation who have not responded to medical therapy and meet specific clinical criteria (such as those from the COAPT trial) are typically candidates.
Why is long-term anticoagulation necessary for TMVR?
Because a prosthetic valve is implanted during TMVR, long-term anticoagulation is required to prevent blood clots from forming on the device (ACC).
Looking Ahead
The future of SMR management lies in “synergistic” treatment options. Emerging transcatheter technologies may soon provide superior alternatives for patients who are currently ineligible for TEER, potentially revolutionizing how severe secondary mitral regurgitation is managed (Journal of Cardiac Failure).
Keep reading